Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimensMahul Amin, Liliane Boccon-Gibod, Lars Egevad, et al.
Scandinavian Journal of Urology and Nephrology. Supplementum|July 16, 2005
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy and pelvic lymphadenectomy specimensJonathan I Epstein, Mahul Amin, Liliane Boccon-Gibod, et al.
European Urology|June 27, 2016
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA TrialChristopher Parker, Steven E Finkelstein, Jeff M Michalski, et al.
The Lancet. Oncology|December 3, 2014
Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trialPeter Hoskin, Oliver Sartor, Joe M O'Sullivan, et al.
European Journal of Cancer (Oxford, England : 1990)|January 22, 2023
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastasesCamilla Thellenberg-Karlsson, Egils Vjaters, Marju Kase, et al.
Clinical Genitourinary Cancer|October 2, 2012
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastasesSten Nilsson, Lars Franzén, Christopher Parker, et al.
The Lancet. Oncology|June 5, 2007
Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II studySten Nilsson, Lars Franzén, Christopher Parker, et al.
Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.
International Journal of Oncology|November 16, 2012
Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 GyJeff R Cortés-González, Enrique Castellanos, Katinka Sandberg, et al.
The Lancet. Oncology|January 9, 2013
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trialPirkko-Liisa Kellokumpu-Lehtinen, Ulrika Harmenberg, Timo Joensuu, et al.
Pageof 11